| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_04b095d095976175317ba7908cc1ed3f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-344
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 |
| filingDate |
2022-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa75cde24b72eff07cc02421180c90e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d1fb6d9b4280808fc0c5b04898720d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_222874b54b171a1bf49e9bac43731753
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edaab5dcfb0a1e2d15d6c576037bf649
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac0d2d56db46c905dbcaaa7845fc5a87 |
| publicationDate |
2022-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022267775-A1 |
| titleOfInvention |
CANCER TREATMENT USING TARGETED siRNA PHARMACEUTICAL FORMULATIONS TO DOWNREGULATE EXPRESSION OF PRDM14 PROTEIN |
| abstract |
Pharmaceutical formulations for the treatment of cancer comprising novel siRNAs that downregulate expression of the PRDM oncoprotein gene and inhibit tumor growth. siRNAs designed and selected to destroy PRDM14 mRNA are described. The siRNAs are delivered via one or more targeted drug delivery systems equipped with a tumor-specific targeting ligand that confers specific binding of the nanoparticle with siRNA payload to receptors on the surface of tumor cells. |
| priorityDate |
2019-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |